Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amisulpride: progress and outcomes.

Y Lecrubier1

  • 1The French Institute of Health and Medical Research, Hĵpital La Salpêtrière, Paris.

Current Medical Research and Opinion
|November 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Improved ability to identify symptoms of major depressive disorder (MDD) in general practice.

International journal of psychiatry in clinical practice·2014
Same author

The impulsivity rating scale (IRS): preliminary results.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Introduction.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

DSM-IH-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Characteristics, recognition and treatment of dysthymics in primary care.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same author

Measures of anhedonia and hedonic responses to sucrose in depressive and schizophrenic patients in comparison with healthy subjects.

European psychiatry : the journal of the Association of European Psychiatrists·2009
Same journal

Clinical and healthcare resource utilization outcomes following revision knee arthroplasty with and without a gradually reducing radius revision knee system.

Current medical research and opinion·2026
Same journal

Medication adherence measurement methods and their reported relationship with medication safety outcomes: a scoping review.

Current medical research and opinion·2026
Same journal

BMI response to dapagliflozin with or without semaglutide across obesity classes: a real-world observational study conducted in Saudi Arabia.

Current medical research and opinion·2026
Same journal

Comparative efficacy of tislelizumab + FOLFOX or CAPOX for gastric/gastroesophageal junction adenocarcinoma: an exploratory matching-adjusted indirect comparison.

Current medical research and opinion·2026
Same journal

Seizing the opportune moment: early use of antiplatelet therapy for thrombolysis.

Current medical research and opinion·2026
Same journal

The importance of patient life engagement as a treatment goal in adults living with schizophrenia: a plain language summary.

Current medical research and opinion·2026
See all related articles

Amisulpride effectively treats schizophrenia by selectively blocking D2/D3 receptors, improving both positive and negative symptoms. It shows comparable or superior efficacy to haloperidol and risperidone with fewer side effects and better quality of life outcomes.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Schizophrenia presents complex positive and negative symptoms, often linked to dopaminergic dysregulation.
  • Current antipsychotics vary in efficacy and side effect profiles, necessitating targeted treatments.

Purpose of the Study:

  • To evaluate the efficacy and tolerability of amisulpride in treating schizophrenia.
  • To compare amisulpride's effects against established antipsychotics like haloperidol and risperidone.

Main Methods:

  • Clinical trials assessing amisulpride in acute and medium/long-term schizophrenia treatment.
  • Utilized rating scales including Clinical Global Impression (CGI), Simpson-Angus Scores (SAS), Brief Psychiatric Rating Scale (BPRS), and Positive and Negative Symptom Score (PANSS).

Related Experiment Videos

Main Results:

  • Amisulpride demonstrated comparable efficacy to haloperidol in acute schizophrenia, with greater patient response (CGI) and fewer extrapyramidal symptoms (EPS).
  • It showed similar efficacy to risperidone, with a trend towards better negative symptom improvement and comparable EPS.
  • Amisulpride uniquely improved negative symptoms, quality of life (QLS, CGI, FSQ), and had a low potential for weight gain.

Conclusions:

  • Amisulpride is an effective atypical antipsychotic with specific clinical advantages for schizophrenia.
  • Its selective D2/D3 receptor blockade offers simultaneous treatment for dopaminergic imbalances, addressing both positive and negative symptoms.
  • Amisulpride offers a favorable side effect profile, including reduced EPS and weight gain, and improves patient functioning and quality of life.